Obesity, a pandemic of the modern world, is intimately associated with dyslipidemia, which
is mainly driven by the effects of insulin resistance and pro-inflammatory adipokines …

Unknown 15 years ago, PCSK9 (proprotein convertase subtilisin/kexin type 9) is now
common parlance among scientists and clinicians interested in prevention and treatment of …

Aims PCSK9 is secreted into the circulation, mainly by the liver, and interacts with low-
density lipoprotein receptor (LDLR) homologous and non-homologous receptors, including …

The proprotein convertase subtilisin/kexin-type 9 (PCSK9) binds to low-density lipoprotein
receptors (LDLR), thereby trafficking them to lysosomes upon endocytosis and enhancing …

Aims PCSK9 loss of function genetic variants are associated with lower low-density
lipoprotein cholesterol but also with higher plasma glucose levels and increased risk of Type …

Characterized as a chronic inflammatory disease of the large arteries, atherosclerosis is the
primary cause of cardiovascular disease, the leading contributor of morbidity and mortality …

Cholesterol plays an essential role in determining cell membrane physico-chemical
characteristics and functions. A proper membrane structure is critical in pancreatic β-cells for …

Aims Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been shown to influence
macrophage biology and modulate atherogenesis. We conducted this study to examine the …

For long time, the role of LDL and inflammation in the pathogenesis of atherosclerosis have
been studied independently from each other and only more recently a common platform has …

Pro-protein convertase subtilisin/kexin type 9 (PCSK9) is secreted mostly by hepatocytes
and to a lesser extent by the intestine, pancreas, kidney, adipose tissue, and vascular cells …